A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38th Annual Roth Conference. Iradimed's CEO, Roger Susi, and CFO, Jack Glenn, will host one-on-one meetings between company management...
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial...
Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle 3-hour incubation regimen identified as the most promising protocol for further clinical development Acne vulgaris represents a promising potential future...
PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited...
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S. Patent Trial and...
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ETPORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that...
Conference Call Scheduled for today, February 17, 2026, at 5:00pm ETGARDNER, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and...
Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk...
GARDNER, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has...